

Index to Public Law Correspondence

1. Dear Manufacturer Letter dated **November 20, 1992**, annual guidance.
2. Dear Manufacturer Letter dated **December 30, 1992**, regarding request for increase to the FCP.
3. Dear Radiopharmacy Operator Letter dated **February 3, 1993**, regarding whether Radiopharmacies need to enter into Master Agreements.
4. Dear Manufacturer Letter dated **February 24, 1993**, regarding request for increase to the FCP.
5. Assistant General Counsel letter to DAS for A&MM dated **March 29, 1993** regarding Impact of Public Law 102-585 on FSS Contract Pricing.
6. Dear Radiopharmaceutical Industry Member Letter dated **April 16, 1993**, regarding agreement between the Department and the manufacturer that Radiopharmacies will not be considered wholesalers.
7. Dear Member of the I.V. Solutions Industry Letter dated **April 22, 1993**, regarding the covered status of I.V. Solutions.
8. Dear Manufacturer Letter dated **May 4, 1993**, regarding technical amendment to the P.L. (dual pricing).
9. OGC Letter dated **May 27, 1993**, regarding transfer of covered drugs (see also Dear Manufacturer letter dated October 15, 1997).
10. Dear Manufacturer Letter dated **June 4, 1993**, regarding sales from "any State or Territory of the United States, the District of Columbia, and the Commonwealth of Puerto Rico".
11. General Counsel Letter dated **July 15, 1993**, regarding delegation of Hearing Responsibility, Title VI, P.L. 102-585, Drug Pricing Agreements.
12. Dear Manufacturer Letter dated **September 23, 1993**, regarding additions of new covered drugs.
13. Dear Manufacturer Letter dated **October 19, 1993**, annual guidance.
14. Dear I.V. Solution Manufacturer Letter dated **October 29, 1993**, regarding covered drug status of certain I.V. Solutions.

15. Dear Manufacturer Letter dated **September 1, 1994**, annual guidance.
16. Dear Manufacturer Letter dated **September 25, 1995**, conveying common errors observed by OIG in the computation of the FCPs.
17. Dear Manufacturer Letter dated **September 25, 1995**, annual guidance.
18. Dear Manufacturer Letter dated **October 7, 1996**, supplementary guidance regarding nominal prices, drug samples and TRICARE.
19. Dear Manufacturer Letter dated **October 16, 1996**, annual guidance.
20. Dear Manufacturer Letter dated **February 11, 1997**, regarding penny prices for single schedule companies.
21. Dear Manufacturer Letter dated **October 15, 1997**, regarding record retention, 2-step computation, transferring covered drugs from one manufacturer to another, and custom or private label packaging.
22. Dear Manufacturer Letter dated **October 16, 1997**, annual guidance.
23. Letter from Pharmacia and Upjohn dated **October 27, 1997**, regarding private label packaging.
24. Response to Pharmacia Letter dated **November 21, 1997**.
25. Office of General Counsel Letter dated **May 8, 1998**, regarding calculation of FCPs for Flu Vaccines.
26. Dear Manufacturer Letter dated **October 16, 1998**, annual guidance.
27. Dear Manufacturer Letter dated **October 18, 1999**, all previous correspondence.
28. Dear Manufacturer Letter dated **October 19, 1999**, annual guidance.
29. Dear Manufacturer Letter dated **October 18, 2000**, annual guidance.
30. Dear Manufacturer Letter dated **October 19, 2001**, annual guidance.
31. Dear Manufacturer Letter dated **October 19, 2001**, regarding who is a manufacturer under a licensing agreement, determination regarding certain purchases by INS, exclusion of sales to § 602 entities at less than the statutory price through their PPV's, and calculation of new covered drug pricing.